ArticleMammalian genome : official journal of the International Mammalian Genome Society2007
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 47 citations in OpenAlex.
- Chromatin remodeling complexes: architects influencing breast cancer progression.Frontiers in cell and developmental biology · 2025Review
- Article
- Comprehensive Analysis of the Expression, Prognosis, and Immune Infiltrates for Chromodomain-Helicase-DNA-Binding Proteins in Breast Tumor.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Triple-negative breast tumors are dependent on mutant p53 for growth and survival.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Chemical sensors for imaging total cellular aliphatic aldehydes in live cells.Chemical science · 2023Article
- Genetic modifiers of p53: opportunities for breast cancer therapies.Oncotarget · 2023Article
- Is loss of p53 a driver of ductal carcinoma in situ progression?British journal of cancer · 2022Review
- Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.Cancer research · 2022Article
- Article
- Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models.Life science alliance · 2021Article
- Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland.Journal of mammary gland biology and neoplasia · 2021Article
- Distinct Tumor Microenvironments Are a Defining Feature of Strain-Specific CRISPR/Cas9-Induced MPNSTs.Genes · 2020Article
- Increased susceptibility to mammary carcinogenesis and an opposite trend in endometrium inJournal of toxicologic pathology · 2019Article
- Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.Bioorganic & medicinal chemistry · 2018Article
- Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driver-Dependent Manner.Cancer research · 2017Article
- Physical Confirmation and Comparative Genomics of the RatG3 (Bethesda, Md.) · 2017Article
- The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.The Journal of pathology · 2017Article
- The Effects of Genetic Background of Mouse Models of Cancer: Friend or Foe?Cold Spring Harbor protocols · 2016Article
- Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
Abstract
BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in a p53 heterozygous state. C57BL/6J mice are resistant to induced mammary tumors and develop less than 1% mammary tumors in both wild-type and p53+/- states. To map modifiers of mammary tumorigenesis, we have established F1 and F2 crosses and backcrosses to BALB/cJ (N2-BALB/cJ) and C57BL/6J (N2-C57BL/6J) strains. All cohorts developed mammary carcinomas in p53+/- females, suggesting that multiple loci dominantly and recessively contributed to mammary tumorigenesis. We mapped two modifiers of mammary tumorigenesis in the BALB/cJ strain. Mtsm1 (mammary tumor susceptibility modifier), a dominant-acting modifier, is located on chromosome 7. Mtsm1 is suggestive for linkage to mammary tumorigenesis (p = 0.001). We have analyzed the Mtsm1 region to locate candidate genes by comparing it to a rat modifier region, Mcs3, which shares syntenic conservation with Mtsm1. Expression data and SNPs were also taken into account. Five potential candidate genes within Mtsm1 are Aldh1a3, Chd2, Nipa2, Pcsk6, and Tubgcp5. The second modifier mapped is Mtsm2, a recessive-acting modifier. Mtsm2 is located on chromosome X and is significantly linked to mammary tumorigenesis (p = 1.03 x 10(-7)).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.